Specimen Table

Cohort Population Genomic DNA RNA Plasma Serum CSF Whole Blood Urine Saliva (Passive Drool) Whole Blood Pellet
PDBP PD and PD-like Cases, Controls
BioFIND Moderately Advanced PD, Controls
STEADYPD3 Early PD
SUREPD3 Early PD

Study Details

Parkinson’s Disease Biomarkers Program (PDBP)

The National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP) was developed to accelerate the discovery of promising new diagnostic and progression biomarkers for Parkinson's disease. PDBP was established to promote the discovery of biomarker candidates for early detection and measurement of disease progression.

Study Subjects

Subjects are recruited and evaluated at one of 9 PDBP-funded research studies, located throughout the United States. Study subjects include individuals at various stages of Parkinson disease (PD) as well as controls. Basic study population information can be seen here.

Available Data

PDBP-funded research studies collect a minimal dataset for each evaluated subject. More information on study data is available here.

Available Biospecimens

DNA and RNA from blood, plasma, serum, whole blood, and CSF are available for request.

BioFIND

BioFIND is a cross-sectional clinical study, designed to discover and verify biomarkers of Parkinson's disease. It is sponsored by the Michael J. Fox Foundation with support from the National Institute of Neurological Disorders and Stroke. Investigators who request access to the BioFIND resource will be required to comply with the BioFIND Biospecimens User Agreement and/or the Data Use Agreement and to adhere to the Publication Policy.

Study Subjects

126 well-defined, moderately advanced PD patients and 106 healthy controls

Available Data

Demographic information, neurological history, medication history, MoCA (Montreal Cognitive Assessment), ADL (Activities of Daily Living), MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease Rating Scale), Hoehn and Yahr Stage, and Sleep/RBD (REM Sleep Behavior Disorder) questionnaire. All data are de-identified to protect patient privacy.

Available Biospecimens

DNA and RNA from blood, plasma, whole blood pellet, CSF, urine and saliva.

STEADY-PDIII

The STEADY-PD III study was conducted to establish efficacy of isradipine to slow progression of Parkinson's disease (PD) disability as determined by the change in the total (Part I-III) Unified Parkinson Disease Rating Scale (UPDRS) score.

Study Subjects

366 subjects with early idiopathic PD not requiring dopaminergic therapy were enrolled into the study. De-identified measures of neurological function, severity of PD, cognition, and mood are available for study subjects. There are no matching controls as part of this cohort.

Available Data

Measures of neurological function, severity of PD, cognition, and mood. All data are de-identified to protect patient privacy.

Available Biospecimens

DNA from blood and plasma

**Baseline samples were collected on PD meds; samples at follow-up visits were collected off PD meds.

SURE-PDIII

SURE-PD3 was a Phase III clinical trial to examine if increasing levels of Urate decelerate disease progression in recently-diagnosed individuals who have not begun dopaminergic therapy. Investigators who request access to this resource will be required to comply with the BioSEND Biospecimens User Agreement and/or the Data Use Agreement and to adhere to the Publication Policy.

Study Subjects

The Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3) was intended to be a two year, placebo-controlled, double-blinded trial of oral inosine treatment in individuals with PD. This trial was concluded early due to lack of effect of the treatment on the primary outcome measure of disease progression. Specimens were collected for plasma over several visits: at baseline, after up to 24 of treatment, and 3 months (of washout) later. There are a total of 287 subjects available; 192 have both plasma and DNA available, with the remaining 95 subjects having only plasma.

Available Data

Measures of neurological function, severity of PD, cognition, and mood. All data are de-identified to protect patient privacy.

Available Biospecimens

DNA from blood and plasma.